Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy

To date, diverse combination therapies with immune checkpoint inhibitors (ICIs), particularly oncolytic virotherapy, have demonstrated enhanced therapeutic outcomes in cancer treatment. However, high pre-existing immunity against the widely used adenovirus human serotype 5 (AdHu5) limits its extensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ping, Wang, Xuchen, Xing, Man, Yang, Xi, Wu, Mangteng, Shi, Hongyang, Zhu, Caihong, Wang, Xiang, Guo, Yingying, Tang, Shubing, Huang, Zhong, Zhou, Dongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118129/
https://www.ncbi.nlm.nih.gov/pubmed/35615266
http://dx.doi.org/10.1016/j.omto.2022.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118129/
https://www.ncbi.nlm.nih.gov/pubmed/35615266
http://dx.doi.org/10.1016/j.omto.2022.04.007

Ejemplares similares